RY 141.08 0.0851% TD 77.38 0.8077% SHOP 80.58 -5.633% CNR 174.21 0.0862% ENB 51.67 1.0364% CP 113.34 0.3808% BMO 128.16 0.5729% TRI 229.48 -0.0566% CNQ 104.59 -1.4046% BN 60.46 -0.0496% ATD 75.69 1.244% CSU 3736.3 -2.3672% BNS 65.67 0.1831% CM 67.55 0.5508% SU 54.79 -0.2549% TRP 52.78 1.1111% NGT 58.11 -0.7854% WCN 228.73 0.6778% MFC 35.6 1.1651% BCE 46.39 0.3461%
Last update at 2024-05-10T20:00:00Z
| Breakdown | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
| Income before tax | -2.67566M | -1.83157M | -0.67580M | -2.04539M | -2.10645M |
| Minority interest | - | - | - | - | - |
| Net income | -2.67566M | -1.83158M | -0.67580M | -2.04539M | -2.10645M |
| Selling general administrative | 1.04M | 0.75M | 0.53M | 1.21M | 1.04M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 0.30M | 0.30M | 1.72M | 0.57M | 0.42M |
| Reconciled depreciation | 0.21M | 0.21M | 0.21M | 0.19M | 0.02M |
| Ebit | - | -1.45322M | -0.18423M | -1.30016M | -1.29603M |
| Ebitda | - | -1.06724M | 0.19M | -1.12659M | -1.27717M |
| Depreciation and amortization | - | - | - | - | - |
| Non operating income net other | - | - | - | - | - |
| Operating income | -1.77814M | -1.26954M | 0.00590M | -1.30016M | -1.29603M |
| Other operating expenses | - | - | - | - | - |
| Interest expense | 0.89M | 0.55M | 0.65M | 0.73M | 0.81M |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | - | - | - |
| Net interest income | -0.89752M | -0.56203M | -0.68169M | -0.74523M | -0.81041M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | - | - | - | - |
| Total revenue | 0.43M | 0.95M | 2.14M | 0.92M | 0.53M |
| Total operating expenses | 2.21M | 2.22M | 2.14M | 2.22M | 1.82M |
| Cost of revenue | 0.13M | 0.65M | 0.42M | 0.35M | 0.10M |
| Total other income expense net | - | - | - | - | -0.81041M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -2.67566M | -1.83157M | -0.67580M | -2.04539M | -2.10645M |
| Net income applicable to common shares | - | -1.83158M | -0.67580M | -2.04539M | -2.10645M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
| Total assets | 3.65M | 3.83M | 3.89M | 3.40M | 0.25M |
| Intangible assets | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | - | - | - | - |
| Total liab | 18.68M | 16.19M | 19.61M | 18.96M | 13.77M |
| Total stockholder equity | -15.03166M | -12.35600M | -15.72390M | -15.56235M | -13.51696M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | - | 0.61M | 1.23M | 1.30M | 2.07M |
| Common stock | - | 68.35M | 63.90M | 63.42M | 63.42M |
| Capital stock | 68.35M | 68.35M | 63.90M | 63.42M | 63.42M |
| Retained earnings | -97.95910M | -95.28345M | -93.45187M | -92.77607M | -90.73069M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | - | - |
| Cash | 0.01M | 0.03M | - | 0.40M | 0.09M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 15.73M | 14.14M | 17.41M | 15.81M | 13.77M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 7.25M | 6.11M | 9.23M | 9.07M | 8.52M |
| Short term debt | - | - | - | - | 8.61M |
| Short long term debt | 6.14M | 6.10M | 9.19M | 8.62M | 8.61M |
| Short long term debt total | - | - | - | - | - |
| Other stockholder equity | - | 14.58M | 13.82M | 13.79M | 13.79M |
| Property plant equipment | - | 2.17M | 2.31M | 2.48M | 0.00674M |
| Total current assets | 1.69M | 1.66M | 1.58M | 0.91M | 0.25M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -12.35850M | -15.72640M | -15.56485M | -13.51947M |
| Short term investments | - | - | - | - | - |
| Net receivables | 1.26M | 1.37M | 1.25M | 0.21M | 0.04M |
| Long term debt | 1.12M | 0.04M | 0.04M | 0.85M | - |
| Inventory | 0.18M | 0.20M | 0.24M | 0.22M | 0.11M |
| Accounts payable | 3.26M | 2.75M | 2.70M | 2.31M | 1.75M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | - | 0.00674M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1.96M | 2.17M | 2.31M | 2.48M | 0.00674M |
| Capital lease obligations | 2.01M | 2.16M | 2.30M | 2.44M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
| Investments | -0.00127M | -0.06972M | -0.03655M | -0.10188M | 0.00334M |
| Change to liabilities | - | -0.57187M | 0.32M | 1.06M | 0.13M |
| Total cashflows from investing activities | - | -0.06972M | -0.03655M | -0.10188M | 0.00334M |
| Net borrowings | - | 0.35M | -0.37493M | 0.73M | 1.03M |
| Total cash from financing activities | 1.25M | 1.99M | 0.14M | 0.73M | 1.03M |
| Change to operating activities | - | 0.39M | 0.70M | 0.76M | 0.92M |
| Net income | -2.67566M | -1.83158M | -0.67580M | -2.04539M | -2.10645M |
| Change in cash | -0.02028M | 0.03M | -0.40186M | 0.31M | 0.09M |
| Begin period cash flow | 0.03M | 0.00000M | 0.40M | 0.09M | 0.00000M |
| End period cash flow | 0.01M | 0.03M | 0.00000M | 0.40M | 0.09M |
| Total cash from operating activities | -1.26775M | -1.88396M | -0.50464M | -0.31590M | -0.94113M |
| Issuance of capital stock | 0.00000M | 1.67M | 0.52M | - | - |
| Depreciation | 0.21M | 0.21M | 0.21M | 0.19M | 0.02M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 0.02M | 0.03M | -0.01319M | -0.11633M | 0.08M |
| Change to account receivables | -0.01117M | 0.00056M | -1.04286M | -0.16867M | 0.00912M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | - | 0.72M | 0.03M | 0.03M | 0.03M |
| Change to netincome | - | - | - | - | -0.01250M |
| Capital expenditures | 0.00127M | 0.07M | 0.04M | 0.10M | 0.10M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 1.20M | -0.26467M | -0.03664M | 1.54M | 1.16M |
| Stock based compensation | - | - | - | - | 0.00000M |
| Other non cash items | - | - | - | - | -0.01250M |
| Free cash flow | -1.26902M | -1.95367M | -0.50464M | -0.31590M | -0.94113M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MIR MedMira Inc |
-0.005 5.56% | 0.09 | - | - | 170.46 | - | 189.94 | -48.7372 |
| NGEN NervGen Pharma Corp |
0.05 2.48% | 2.07 | - | - | - | 29.48 | -6.9477 | |
| ARCH Arch Biopartners Inc |
0.01 0.59% | 1.71 | - | - | 37.82 | - | 53.05 | -28.1027 |
| TTI Thiogenesis Therapeutics Corp. |
0.03 4.29% | 0.73 | - | - | - | 11.86 | -163.0787 | |
| SBM Sirona Biochem Corp |
- -% | 0.07 | - | - | 343.74 | 41.64 | 359.74 | -13.882 |
MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis. It also provides Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics; and Reveal G4 HIV tests. In addition, the company offers VYRATM TriDemic antigen rapid test that distinguishes the three respiratory viruses, such as SARS-CoV-2, influenza, and respiratory syncytial virus that exhibit similar symptoms. It sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.
155 Chain Lake Drive, Halifax, NS, Canada, B3S 1B3
| Name | Title | Year Born |
|---|---|---|
| Mr. Hermes Chan | Co-Founder, CEO, Pres & Director | NA |
| Mr. Markus M. Meile | Chief Financial Officer | NA |
| Stewart McKelvey | Legal Counsel | NA |
| Dr. Kevin D. Jones | Head of Commercialization and Sr. Director of Sales & Marketing | 1969 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
CA 
AU
UK
US
NZ
Please wait processing your request...